Company: Alzheon Inc.
Symbol: ALZH
Description: They are a clinical stage biopharmaceutical company with a Phase 3-ready program in Alzheimers disease and a discovery platform of small molecules for the inhibition of protein misfolding in neurodegenerative disorders.
Trade Date: 4/12
Shares: 5 million
Price Range: $13.00-$15.00
Underwriter(s): Citigroup, Piper Jaffray
Co-Manager(s): Canaccord Genuity, JMP Securities
Terms Added: 4-2-18
Business: Their lead product candidate, ALZ-801, is an orally administered inhibitor of beta amyloid misfolding. Beta amyloids are protein fragments that, when they misfold, form small neurotoxic aggregates, or oligomers. They believe that they are the only company developing a clinical stage small molecule with a mechanism of action designed to prevent the misfolding and aggregation of beta amyloid protein into neurotoxic oligomers. In their post hoc analyses of data from 16 clinical trials conducted by Bellus Health, Inc., they observed promising clinical signals in a subset of patients with two copies of the APOE4 gene, or APOE4/4 homozygotes, who have greater beta amyloid burden and develop AD earlier. To their knowledge, of the 87 product candidates currently in clinical development for AD, eight, including ALZ-801, have received Fast Track designation. Their platform includes multiple proprietary libraries of over 10 unique chemotypes representing chemical diversity of more than 5,000 compounds with the potential to inhibit protein misfolding and disrupt protein-protein interactions, and prevent pathogenic processes leading to neurodegeneration. They are developing and optimizing the next generation of protein misfolding inhibitors for neurodegenerative diseases.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish